Intranasal Esketamine for Treating Inpatients with Borderline Personality Disorder and Comorbid Treatment-Resistant Depression – a Retrospective Chart Review Study
Hannah Tramontano, Jeffrey Fetter, Mohamed Wagdy ElSayed preprint
Background: Borderline Personality Disorder (BPD) affects 1.35% of the population and is frequently comorbid with Major Depressive Disorder (MDD), which is frequently treatment-resistant (TRD). Patients with comorbid illness have worse treatment outcomes and functional impairment. Esketamine could ameliorate symptoms of both illnesses. Methods: We conducted a retrospective chart review of...